Colorectal Cancer Research

Getting treated for colorectal cancer at City of Hope means you are steps away from labs where new treatments are being developed every day. That proximity means you will benefit from something unique in cancer care — bench to bedside treatment. "Bench to bedside" means exciting new research we are conducting in our labs is moved quickly to the bedside to treat our patients.

Colorectal cancer is an extremely complex disease that can act many different ways in the body. Clinical trials at City of Hope are focused on those differences — and designing therapies that affect how colorectal cancer develops, progresses and spreads:

• 24589: FOLFOX, Botensilimab, and Balstilimab for the treatment of localized rectal cancer before surgery
• 24405: Papaverine in combination with radiation therapy for the treatment of locally advanced rectal cancer, DINOMITE trial
• 24372: Minimal residual disease testing for the early detection of cancer recurrence in resectable stage II-IV colorectal cancer patients
• 22190: ADG126 in combination with pembrolizumab in patients with advanced/metastatic solid tumors
• 24706: Evaluation of the safety and efficacy of treatment with high dose melphalan given directly into the liver followed by treatment with approved cancer treatment or approved cancer treatment alone in patients with metastatic colorectal cancer with liver dominant disease (DEL-LIVER)
• 25009: A phase 2 study of Leronlimab in combination with TAS-102 + Bevacizumab in previously treated participants with mCRC
• 25558: Phase III study of Ivonescimab or Bevacizumab combined with FOLFOX in patients with metastatic colorectal cancer (HARMONi-GI3)

In addition to these clinical trials, City of Hope has several others that will open soon that look at new therapies for patients with specific mutations called RAS, and will explore new immunotherapy approaches, which is a way of helping the patient’s own immune system fight cancer.